Prevalence and risk factors of long COVID 6-12 months after infection with the Omicron variant among nonhospitalized patients in Hong Kong
- PMID: 37334978
- DOI: 10.1002/jmv.28862
Prevalence and risk factors of long COVID 6-12 months after infection with the Omicron variant among nonhospitalized patients in Hong Kong
Abstract
Long COVID has been reported among patients with COVID-19, but little is known about the prevalence and risk factors associated with long COVID 6-12 months after infection with the Omicron variant. This is a large-scale retrospective study. A total of 6242 out of 12 950 nonhospitalized subjects of all ages with SARS-CoV-2 infection (confirmed by polymerase chain reaction/rapid antigen test) during the Omicron dominant outbreak (December 31, 2021-May 6, 2022) in Hong Kong were included. Prevalence of long COVID, frequencies of symptoms, and risk factors were analyzed. Three thousand four hundred and thirty (55.0%) subjects reported at least one long COVID symptom. The most reported symptom was fatigue (1241, 36.2%). Female gender, middle age, obesity, comorbidities, vaccination after infection, having more symptoms, and presenting fatigue/chest tightness/headache/diarrhea in the acute stage of illness were identified as associated risk factors for long COVID. Patients who had received three or more doses of vaccine were not associated with a lower risk of long COVID (adjusted odds ratio 1.105, 95% confidence interval 0.985-1.239, p = 0.088). Among patients with at least three doses of vaccine, there was no significant difference in the risk of long COVID between the CoronaVac vaccine and BNT162b2 vaccine (p > 0.05). Omicron infection can lead to long COVID in a significant proportion of nonhospitalized patients 6-12 months after infection. Further investigation is needed to uncover the mechanisms underlying the development of long COVID and determine the impact of various risk factors such as vaccines.
Keywords: Omicron; long COVID; risk factors; symptom.
© 2023 Wiley Periodicals LLC.
Comment in
-
Risk factors of long COVID 6-12 months after infection with the Omicron variant among nonhospitalized patients.J Med Virol. 2023 Nov;95(11):e29235. doi: 10.1002/jmv.29235. J Med Virol. 2023. PMID: 37970745 No abstract available.
Similar articles
-
Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.Lancet Infect Dis. 2023 Apr;23(4):421-434. doi: 10.1016/S1473-3099(22)00732-0. Epub 2022 Dec 12. Lancet Infect Dis. 2023. PMID: 36521506 Free PMC article.
-
Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study.Lancet Psychiatry. 2023 Jun;10(6):403-413. doi: 10.1016/S2215-0366(23)00111-6. Epub 2023 May 1. Lancet Psychiatry. 2023. PMID: 37141907 Free PMC article.
-
Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.Lancet Microbe. 2023 Jun;4(6):e418-e430. doi: 10.1016/S2666-5247(23)00006-X. Epub 2023 Apr 20. Lancet Microbe. 2023. PMID: 37086735 Free PMC article.
-
Effectiveness of BNT162b2 and Sinovac vaccines against the transmission of SARS-CoV-2 during Omicron-predominance in Hong Kong: A retrospective cohort study of COVID-19 cases.J Clin Virol. 2023 Sep;166:105547. doi: 10.1016/j.jcv.2023.105547. Epub 2023 Jul 10. J Clin Virol. 2023. PMID: 37453162
-
Effectiveness of BNT162b2 and CoronaVac vaccines in preventing SARS-CoV-2 Omicron infections, hospitalizations, and severe complications in the pediatric population in Hong Kong: a case-control study.Emerg Microbes Infect. 2023 Dec;12(1):2185455. doi: 10.1080/22221751.2023.2185455. Emerg Microbes Infect. 2023. PMID: 36852582 Free PMC article.
Cited by
-
Prevalences and Interrelationships of Post COVID-19 Fatigue, Sleep Disturbances, and Depression in Healthy Young and Middle-Aged Adults.J Clin Med. 2024 May 9;13(10):2801. doi: 10.3390/jcm13102801. J Clin Med. 2024. PMID: 38792343 Free PMC article.
-
Proposal and Definition of an Intelligent Clinical Decision Support System Applied to the Prediction of Dyspnea after 12 Months of an Acute Episode of COVID-19.Biomedicines. 2024 Apr 12;12(4):854. doi: 10.3390/biomedicines12040854. Biomedicines. 2024. PMID: 38672208 Free PMC article.
-
High Prevalence of Long COVID in Common Variable Immunodeficiency: An Italian Multicentric Study.J Clin Immunol. 2024 Feb 6;44(2):59. doi: 10.1007/s10875-024-01656-2. J Clin Immunol. 2024. PMID: 38319477 Free PMC article.
-
Exploring the Network between Adipocytokines and Inflammatory Response in SARS-CoV-2 Infection: A Scoping Review.Nutrients. 2023 Aug 30;15(17):3806. doi: 10.3390/nu15173806. Nutrients. 2023. PMID: 37686837 Free PMC article. Review.
References
REFERENCES
-
- WHO. 2023. WHO coronavirus (COVID-19) dashboard. Accessed February 28, 2023. https://covid19.who.int/
-
- Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626-631.
-
- O'Mahoney LL, Routen A, Gillies C, et al. The prevalence and long-term health effects of long covid among hospitalized and non-hospitalized populations: a systematic review and meta-analysis. EClinicalMedicine. 2023;55:101762.
-
- WHO. 2021. A clinical case definition of post COVID-19 condition by a Delphi consensus. Accessed February 13, 2023. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_cond...
-
- Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28(8):1706-1714.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous